IFF Sheds $2.2B Food Unit to CVC in Latest PE Carve-Out Wave

International Flavors & Fragrances has agreed to sell its Food Ingredients business to CVC Capital Partners for $2.2 billion in cash, the latest in a string of corporate carve-outs that have made private equity the default buyer for underperforming divisions at multi-industry conglomerates.

The deal, announced Thursday, will hand CVC a standalone platform with roughly $1.5 billion in annual revenue and operations spanning cultures, enzymes, and specialty ingredients sold into bakery, dairy, and meat processing. It's a bet that what dragged as a subscale unit inside IFF can thrive as a focused business under PE ownership—a thesis that's been tested repeatedly in food ingredients, with mixed results.

IFF expects the transaction to close in the fourth quarter of 2026, subject to regulatory approvals. The $2.2 billion price tag implies a multiple around 9x EBITDA, according to people familiar with the financials—a valuation that sits above recent distressed carve-outs but below the 11-12x range that top-tier specialty ingredients assets commanded in 2024.

For IFF, the sale marks the end of a five-year strategy that tried—and largely failed—to build a diversified ingredients powerhouse through M&A. The company acquired DuPont's Nutrition & Biosciences unit in 2021 for $26.2 billion, a deal that was supposed to transform IFF from a niche flavors-and-fragrances player into a broad-based specialty ingredients giant. Instead, it saddled the company with debt, integration headaches, and a portfolio that never quite fit together.

IFF's decision to exit Food Ingredients isn't surprising. The division has been the lowest-margin segment in the company's portfolio, with EBITDA margins in the mid-teens—well below the 20%+ margins IFF generates in its core Scent and Taste businesses. That gap matters when you're carrying $18 billion in debt and facing activist pressure to simplify.

The company has been under pressure from shareholders to shed non-core assets and pay down leverage since the DuPont deal closed. Activists have circled IFF for the past 18 months, arguing that the conglomerate structure destroys value and that the individual pieces would trade at higher multiples as standalone businesses.

"This is a classic case of a good business trapped inside the wrong parent," said one buy-side analyst who covers IFF. "Food Ingredients requires a different playbook—more volume-focused, more commoditized, less innovation-driven. It never made sense next to high-margin fragrances."

IFF will use the $2.2 billion in proceeds to pay down debt, which currently sits at roughly 5x net leverage. The company has said it wants to reach 3x leverage by the end of 2027, which would require either additional asset sales or significant EBITDA growth. Given flat end-market demand in flavors and fragrances, more divestitures seem likely.

CVC isn't new to food ingredients. The firm has backed several platforms in adjacent categories over the past decade, including nutrition, specialty chemicals, and food additives. Its most notable recent exit was Azelis, a Belgium-based specialty chemicals distributor that CVC took public in 2021 and exited in stages through 2024 at a valuation north of $6 billion.

The IFF Food Ingredients acquisition fits a familiar pattern: buy a carve-out from a distracted parent, install operational leadership, consolidate fragmented customer relationships, and bolt on smaller tuck-ins to build scale. CVC has run this play in everything from packaging to animal nutrition.

What's less clear is whether the unit can grow faster outside IFF's portfolio. Food Ingredients serves deeply cyclical end markets—bakery, dairy, meat processing—that are sensitive to commodity input costs and consumer demand shifts. Margins are thin, switching costs are low, and customer concentration is high. It's a business that rewards operational excellence and scale, not innovation.

The margin gap tells the story. IFF's Food Ingredients unit lags standalone peers by 200-400 basis points on EBITDA margin, a function of shared overhead costs, suboptimal manufacturing footprint, and underinvestment during the integration years. CVC will argue that gap represents upside. Skeptics will say it reflects structural challenges in the business model.

Private equity has become the dominant buyer of corporate carve-outs for a reason: sellers are willing to accept lower valuations in exchange for speed and certainty, and PE firms are willing to stomach integration risk that strategic buyers won't touch. CVC is paying 9x EBITDA for a business that might fetch 11x as a standalone asset in three years—if the operational improvements land.

IFF's Food Ingredients division is a collection of enzyme, culture, and functional ingredient businesses that serve industrial food manufacturers. It's not consumer-facing—there's no brand equity here. Instead, the unit supplies the inputs that extend shelf life, improve texture, enhance fermentation, and reduce waste in large-scale food production.

The product portfolio breaks into three core categories:

Cultures and enzymes for dairy and fermentation—used in yogurt, cheese, and plant-based alternatives. This is the highest-margin segment within Food Ingredients, with some defensibility around proprietary strains and regulatory approvals.

Bakery and cereal enzymes—sold into industrial bread production and breakfast cereal manufacturing. Highly commoditized, with pricing pressure from Asian suppliers and limited differentiation.

Meat and protein ingredients—antimicrobial solutions, shelf-life extenders, and texture modifiers for processed meat. Growing category as food safety regulations tighten, but exposed to volatile livestock cycles and shifting consumer preferences around meat consumption.

Geographically, the business skews toward Europe and North America, which together represent roughly 70% of sales. Emerging markets have been a growth priority for IFF, but penetration remains limited due to customer preference for local suppliers and price sensitivity in developing regions.

Customer concentration is a known risk. The top ten customers—mostly large multinational food processors like Nestlé, Danone, and Tyson—account for an estimated 40% of revenue. Losing one of those anchor accounts would materially impact the P&L, which makes the business less attractive to strategic buyers who want diversification.

IFF's divestiture fits into a broader wave of corporate simplification that has accelerated over the past 18 months. As conglomerates face pressure to improve returns and reduce complexity, non-core divisions are being spun out, sold to PE, or taken public as standalone entities.

In specialty ingredients alone, we've seen DuPont divest multiple units post-merger, BASF explore strategic options for its nutrition and care chemicals divisions, and DSM-Firmenich announce a portfolio review following its own mega-merger. The pattern is consistent: integrate, realize the synergies don't materialize, then sell off the pieces that don't fit.

Private equity has been the buyer in most of these transactions. Strategic acquirers—other large ingredient companies—are either dealing with their own integration issues or wary of taking on subscale assets that require turnaround work. PE firms, by contrast, are sitting on record dry powder and willing to underwrite operational improvement stories, especially in sectors with recurring revenue and defensive end markets.

The risk is that these carve-outs don't perform as standalone businesses. Stranded costs, customer attrition, and underinvestment during the transition period can erode value quickly. CVC will need to move fast on cost structure, leadership, and customer retention to avoid the stumbles that plagued earlier food ingredient carve-outs like Ingredion's specialty starches business or Kerry Group's post-divestiture performance.

The 9x EBITDA multiple CVC is paying sits in the middle of the historical range for specialty food ingredients. Top-tier assets with differentiated technology, high margins, and low customer concentration have traded at 11-13x in recent years. Distressed or commoditized businesses have gone for 6-8x. IFF's Food Ingredients unit falls somewhere in between—defensible in dairy cultures, commoditized in bakery enzymes, and cyclically exposed in meat ingredients.

One benchmark: when Kerry Group sold its sweet ingredients business to Carlyle in 2023, the reported multiple was around 10x EBITDA, but that business had higher margins and less customer concentration. IFF's unit likely merited a discount to that comp, which suggests the $2.2 billion price is fair—but not a steal for CVC.

Selling Food Ingredients solves one problem for IFF—deleveraging—but it doesn't fix the underlying strategic question: what is IFF's right to win in a fragmented ingredients market where scale and focus increasingly matter more than diversification?

The company will still own Scent, Taste, and Health & Biosciences after this deal closes. Scent and Taste are the legacy businesses—high-margin, innovation-driven, relatively insulated from commodity cycles. Health & Biosciences, the other piece of the DuPont acquisition, includes probiotics, enzymes for home care, and pharma excipients. It's a decent business, but it's also been a laggard.

Activists will likely push for more. If IFF can get $2.2 billion for a subscale, low-margin food unit, what could it get for Health & Biosciences, which is larger and has more defensible moats? The pressure to break up the company entirely—splitting Scent from Taste and selling or spinning Health & Biosciences—isn't going away.

The market will watch how IFF deploys the $2.2 billion. If it all goes to debt paydown, investors will cheer the deleveraging but question whether management has a growth plan. If some of it funds buybacks or small M&A, the activist narrative—that IFF should be broken up, not managed as a going concern—will gain momentum.

One thing is clear: the conglomerate model in specialty ingredients is under siege. Companies that assembled sprawling portfolios through M&A in the 2010s are now dismantling them, admitting implicitly that the sum of the parts was worth less together than apart. IFF is late to that realization, but at least it's moving.

CVC is buying a business that has been deprioritized inside IFF for years. That means deferred capex, underinvestment in sales and R&D, and a leadership team that may not have had the autonomy to make tough calls on footprint or product portfolio. Day one, CVC will inherit those structural issues.

The biggest near-term risk is customer attrition. When a carve-out happens, customers get nervous—especially in a relationship-driven business like ingredients, where technical service and supply reliability matter as much as price. If CVC doesn't move quickly to reassure the top 20 accounts and lock in long-term contracts, revenue could erode faster than cost comes out.

The second risk is stranded costs. IFF has historically allocated shared services—IT, HR, finance, supply chain—across its portfolio. Carving out Food Ingredients means either rebuilding those functions from scratch (expensive) or signing a transition services agreement with IFF (which creates dependency and limits operational flexibility). Most carve-outs stumble here, underestimating the true cost to operate standalone.

Third, the business needs capital investment. Manufacturing assets are aging, and the product pipeline has been underfunded. CVC will need to commit incremental capex in year one and two—at a time when it's also trying to reduce overhead and improve margins. That's a tough balancing act, and it's where many PE-backed carve-outs blow up their operating plans.

The IFF-CVC deal is a data point in a broader trend: specialty ingredients is consolidating, and the winners will be focused, scaled platforms—not diversified conglomerates. That means more carve-outs, more PE-backed roll-ups, and more pressure on mid-sized players to either find a niche or sell.

The structural drivers are clear. End markets for food, personal care, and industrial ingredients are growing slowly—low single digits in developed markets, mid-single digits in emerging markets. Innovation cycles are lengthening as regulatory approval timelines stretch. Customers are consolidating, which increases their bargaining power and compresses supplier margins.

In that environment, scale matters. The largest players—DSM-Firmenich, Givaudan, Kerry—can afford the R&D spend, absorb customer concentration risk, and negotiate better terms with raw material suppliers. Mid-sized players like IFF are stuck in the middle: too small to compete on cost, too large to be nimble.

Private equity's role in this reshuffling is to act as the interim owner—buying subscale assets from conglomerates, fixing the cost structure and customer base, then either selling to a strategic at a higher multiple or taking the business public once it's stabilized. It's financial engineering dressed up as operational improvement, but in some cases, it works.

Whether it works for CVC and IFF's Food Ingredients unit will depend on execution—specifically, whether CVC can retain key customers, cut stranded costs faster than revenue erodes, and invest enough in the business to make it attractive to the next buyer. The clock starts ticking the day the deal closes.